Pfizer advised us that it continues to anticipate resuming the dosing of additional patients in the Phase 3 AFFINE trial of giroctocogene fitelparvovec, an investigational gene therapy we are developing with Pfizer for patients with moderately severe to severe hemophilia A, in the third quarter of 2022. Cash, cash equivalents and marketable securities as of June 30, 2022, were $363.7 million, compared to $464.7 million as of December 31, 2021. Non-GAAP operating expenses, which exclude stock-based compensation expense, for the third quarter ended September 30, 2022 were $73.5 million, compared to $69.1 million for the same period in 2021. There are no open jobs at Sangamo Therapeutics, Inc. currently. I had 3 phone/Zoom interviews including with HR and the hiring managers. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. (unaudited; in thousands, except per share data), View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005505/en/, Investor Relations & Media Inquiries Sangamo Therapeutics, Inc.(Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results. I had 3 phone/Zoom interviews including with HR and the hiring managers. General high turnover rate in biotech industry applies here as well. This press release contains forward-looking statements regarding our current expectations. The increase of $1.5 million in revenues was primarily attributed to an increase of $1.3 million in revenue related to our collaboration agreement with Novartis and an increase of $0.8 million in revenue related to our collaboration agreement with Sanofi. Our scientists are leaders in the. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. There can be no assurance that we and our collaborators will be able to develop commercially viable products. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. Sangamo Therapeutics saw global potential for TxCell's lead candidate TX200 as the anchor of a pipeline of chimeric antigen receptor . Research calls posted earlier this morning are available here. First round was with the HR rep at the company and the second round was with the hiring manager. Sangamo Therapeutics stock declined 17% over the last 10 trading days (2 weeks), compared to broader market (S&P500) decline of 2.5%. BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 3, 2022-- Received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for BIVV003. Coworkers are all very helpful and friendly. Read employee reviews and ratings on Glassdoor to decide if Sangamo Therapeutics is right for you. Interviews at Sangamo Therapeutics Experience Positive 38% Negative 44% Neutral 19% Getting an Interview Applied online 33% Employee Referral 25% Recruiter 17% Difficulty 2.8 Average Hard Average Easy Interviews for Top Jobs at Sangamo Therapeutics Project Manager (1) Technician (1) Scientist II (1) Bioinformatics Analyst I (1) Really collaborative environment Great coworkers Very supportive community, Promotions based on seniority rather than merit HR does not really help solve problems, Great people, good environment, interesting science. We continue to actively prepare for a potential pivotal Phase 3 trial. Verify your email to use filters. We are passionate about our science and driven by the purpose it serves. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. Employees also rated Sangamo Therapeutics 4.1 out of 5 for work life balance, 4.5 for culture and values and 3.8 for career opportunities. Why Sangamo? The decrease of $2.1 million in revenues was primarily attributable to a decrease of $1.9 million and $1.6 million related to our collaboration agreements with Novartis and Biogen respectively, and a decrease of $1.1 million due to the termination of our collaboration agreement with Sanofi. Sangamo Therapeutics Inc (NASDAQ: SGMO) announced updated preliminary data as of October 20, 2022, the cutoff date from the Phase 1/2 STAAR study of isaralgagene civaparvovec, or ST-920, a wholly. Apr 28, 2022 - Principal Research Associate, May 10, 2022 - Senior Development Engineer, Sangamo Therapeutics has an overall rating of 4.2 out of 5, based on over 55 reviews left anonymously by employees. Overall, 89% of employees would recommend working at Sangamo Therapeutics to a friend. The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. (This interview has been lightly edited for length and . We dosed the sixth patient in the Phase 1/2 PRECIZN-1 study of BIVV003, a zinc finger nuclease gene-edited cell therapy candidate for the treatment of sickle cell disease. According to reviews on Glassdoor, employees commonly mention the pros of working at Sangamo Therapeutics to be benefits, career development, culture and the cons to be senior leadership, compensation, management. The process took 4 weeks. Our goal is to develop a wholly owned genomic medicine portfolio, which we fund via our collaborations with blue-chip biopharmaceutical partners, which have already brought in $815M in upfronts and milestones with billions in potential milestone payments. Interview process length. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Both sides asked questions and got the answers we need, and after the interview, I was even more excited to join the company. Minimum 15 minutes delayed. Salary expectation. Presented seven posters and one oral presentation at ASGCT on. Supervisors are flexible. We were proud to present promising updated preliminary data from our wholly owned Fabry study, to resume our partnered Hemophilia A pivotal trial, and to continue dosing in our renal transplant rejection and sickle cell studies. How is diversity at Sangamo Therapeutics? Glassdoor users rated their interview experience at. We completed manufacturing of the dose for the second patient, who recently received a kidney transplant. Background and experience. The call will also be webcast with live Q&A and can be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. A pivotal data readout is estimated in late 2023 or early 2024. The hiring process at Sangamo Therapeutics takes an average of 31 days when considering 17 user submitted interviews across all job titles. To learn more, visit www.sangamo.com and connect with us on LinkedIn and Twitter. Nothing striking about this particular process. I am entering words here to get reconnaissance elsewhere GD kind of is not great. Candidates interviewing for Project Manager Biotech and Research Intern rated their interviews as the hardest, whereas interviews for Project Manager and Bioinformatics Analyst I roles were rated as the easiest. When did GD start to be awful? We have a robust preclinical pipeline with programs in emerging areas that could provide value in the mid-to-long term. Consolidated net loss for the second quarter ended June 30, 2022, was $43.2 million, or $0.29 per share, compared to a net loss of $47.2 million, or $0.33 per share, for the same period in 2021. Working in the company was very fun, I learned a lot about the technology that the company uses and about the different methodologies and techniques Sangamo has. We have raised approximately $75.1 million in net proceeds under our at-the-market offering program from January 1, 2022 through October 31, 2022. When did GD start to be awful? Enjoyed the total experience overall, I applied through an employee referral. A change of -17% or more over 10 trading days is a 9% . Since the cutoff date, the fifth and final patient in the dose escalation phase who started the study on ERT has been withdrawn from ERT. Guided by Science. Tell me about yourself? Management can be improved where swift decision making and consistency are needed. Background and experience. I applied through a recruiter. We expect to present updated data from the Phase 1/2 PRECIZN-1 study via a poster presentation at the 64th. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. HR screen is just going over the Job Description and why Sangamo. We expect to present updated data from the Phase 1/2 ALTA study via a poster presentation at the ASH Annual Meeting in December. ProsGreat science and robust pipelines. Three weeks. Due to the split at Richmond and Brisbane, there was confusion on which site to interview. The Sangamo management team will discuss these results on a conference call today, Thursday November 3, 2022, at 4:30 p.m. Eastern Time. Sangamo (SGMO) delivered earnings and revenue surprises of 11.11% and 0.83%, respectively, for the quarter ended December 2022. Tell me a little about your self. View source version on businesswire.com: https://www.businesswire.com/news/home/20220804005384/en/, Louise Wilkieir@sangamo.com We plan to provide guidance on timing for dosing for the third patient once the kidney transplant has been scheduled. Barclays Gene Editing & Gene Therapy Summit. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP financial information, to more fully understand our business. Actual results may differ materially from those projected in these forward-looking statements due to the risks and uncertainties described above and other risks and uncertainties that exist in the operations and business environments of Sangamo and our collaborators. General high turnover rate in biotech industry applies here as well. Winning Companies champion board diversity by having 20% or more of their board seats held by women. Unorganized at best. What are perks and other benefits like at Sangamo Therapeutics? American Society of Gene and Cell Therapy (ASGCT) Profiled significant pre-clinical progress across Sangamos innovative pipeline and platform. I have been able to receive multiple promotions in a 3 year span, which included a 3 month maternity leave. Share your interview experience. Recruiter set up the interview. Duties of the advertised position and the involved project. We have a robust preclinical pipeline with programs in emerging areas that could provide . Now many are ending their programs. - Sustained, elevated expression of alpha-galactosidase A (-Gal A) activity observed in 13 patients for over two years for the longest treated patient as of cutoff date. While not required, it is recommended you join 10 minutes prior to the event start. For Sangamo Therapeutics, science is a means to develop new medicines with the potential to transform the lives of patients living with serious genetic diseases. Do the numbers hold clues to what lies ahead for the stock? This press release contains forward-looking statements regarding our current expectations. Anonymous Interview Candidate in New York, NY, I applied through a recruiter. Progressed clinical activities in preparation for the third patient. I am able to speak with VPs of many different departments with ease. Conference Call to Discuss Second Quarter 2022 Results. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the effects of the evolving COVID-19 pandemic and the impacts of the pandemic and other macroeconomic factors, including as a result of the ongoing conflict between Russia and Ukraine, on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials; the research and development process, including the enrollment, operation and results of clinical trials and the presentation of clinical data; the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients as well as the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study and the Phase 1/2 PRECIZN-1 study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec, or BIVV003 (formerly known as SAR44513); the unpredictable regulatory approval process for product candidates across multiple regulatory authorities, including the potential that health authorities will not issue the required protocol amendment approvals in the Phase 3 AFFINE trial in a timely manner, or at all; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any Phase 3 trial of our product candidates; our limited experience manufacturing biopharmaceutical products, including the risks that we may be unable to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended; the potential for technological developments that obviate technologies used by Sangamo; the potential that Sangamo will not be able to identify and secure options or new collaborators for the BIVV003 program; the potential for Sangamo to cease development of the BIVV003 program, whether due to its inability to secure options to advance the program or otherwise;our lack of resources to fully develop, obtain regulatory approval for and commercialize our product candidates; and our ability to achieve expected future financial performance. Interviews at Sangamo Therapeutics Experience Positive 38% Negative 44% Neutral 19% Getting an Interview Applied online 33% Employee Referral 25% Recruiter 17% Difficulty 2.8 Average Hard Average Easy Interviews for Top Jobs at Sangamo Therapeutics Project Manager (1) Technician (1) Scientist II (1) Bioinformatics Analyst I (1) The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Four patients were withdrawn from enzyme replacement therapy (ERT) and maintained significantly elevated levels of -Gal A activity up to 28 weeks post withdrawal. Skip to main navigation Science Overview Zinc Finger Cell Therapy Genome Regulation Bioethics We completed the transition of Sanofis rights and obligations under the collaboration developing BIVV003, formerly known as. I wasn't happy with the unprofessional manner. 38% of job seekers rate their interview experience at Sangamo Therapeutics as positive. Good people, culture, benefits and great pipeline projects. Employees rate Sangamo Therapeutics 4.2 out of 5 stars based on 55 anonymous reviews on Glassdoor. This rating has improved by 1% over the last 12 months. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. Our pipeline progress is expected to yield additional data in Q4 and into 2023. We expect to present additional clinical updates from the STAAR study, including the first data from the expansion cohort, in the first half of 2023. The product candidate continues to be generally well tolerated in both patients. Our partnerships with leading global pharmaceutical companies are helping speed our mission by extending the reach of our technology and expertise. Actual results may differ materially from those projected in these forward-looking statements due to the risks and uncertainties described above and other risks and uncertainties that exist in the operations and business environments of Sangamo and our collaborators. All patients withdrawn have remained off ERT. Glassdoor has 55 Sangamo Therapeutics reviews submitted anonymously by Sangamo Therapeutics employees. Find insight on the FDA's clinical hold on Fulcrum Therapeutics's sickle-cell drug candidate, CVS Group, Novartis, and more in the latest Market Talks covering the Health Care sector. Our rare disease clinical programs are feeding insights across our portfolio and paving the way for research and preclinical programs across larger patient populations. Financial Guidance for 2022 Narrowed (initial guidance provided on February 24, 2022). Participants should register for, and access, the call using this link. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. I interviewed at Sangamo Therapeutics in Jul 2021. Pioneering the future of genomic medicine, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease, Phase 3 Trial of Investigational Gene Therapy for Hemophilia A has Resumed Dosing, Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated -Gal A Enzyme Activity in Nine Patients, Pfizer and Sangamo Therapeutics Announce Phase 3 Trial of Investigational Gene Therapy for Hemophilia A has Re-opened Recruitment, European Orphan Medicinal Product Designation Granted to Sangamo Therapeutics Investigational CAR-Treg Cell Therapy TX200 for Solid Organ Transplantation, First-in-human in vivo genome editing via AAV-zinc finger nucleases for mucopolysaccharidosis I/II and hemophilia B, Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies, Poster: STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST 920) gene therapy in adults with Fabry disease, Presentation: STAAR, a Phase 1/2 study of isaralgagene civaparvovec (ST 920) gene therapy in adults with Fabry disease. Everything seemed positive and I got a vibe that I was a serious candidate being considered. We continue to actively prepare for a potential pivotal Phase 3 trial. Fabry disease Received endorsement to progress into the Ph1/2 studys expansion phase; continued to recruit patients and activate sites; Phase 3 planning progresses. Non-GAAP operating expenses, which exclude stock-based compensation expense, for the second quarter ended June 30, 2022, were $67.2 million, compared to $67.1 million for the same period in 2021. Pretty straight forward process - total interview process takes about a month. To supplement our financial results and guidance presented in accordance with GAAP, we present non-GAAP total operating expenses, which exclude stock-based compensation expense from GAAP total operating expenses. Having problems? Coupled with strong advances in our preclinical pipeline, we believe this progress positions us well to advance the development of potentially transformational genomic medicines for patients in need and to generate long-term value for our shareholders.. Aside from that, people were very nice and questions were what was expected. Point Richmond is a nice little downtown area as well. Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline. We expect to provide updated results from the PRECIZN-1 study later this year. View all news about Sangamo Therapeutics, Inc. Each step toward the possibility of eliminating the need for frequent, life-long treatment for the patients and families affected by debilitating disease is exciting. In the third quarter, we continued to advance our clinical trials and preclinical activities while maintaining fiscal discipline and operational excellence, said Sandy Macrae, Chief Executive Officer of Sangamo. Filler, words, noun, verb, et cetera. Patient dosing is expected to resume in October New York, NY, and Brisbane, California, September 22, 2022 - Pfizer and Sangamo Therapeutics announced that the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A, has re-opened recruitment. I interviewed at Sangamo Therapeutics (Richmond, CA) in Jul 2019. This has been a year marked by progress across our pipeline. Currency in USD, Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies. What is the interview process like at Sangamo Therapeutics? Both sides asked questions and got the answers we need, and after the interview, I was even more excited to join the company. As of the November 15, 2022, supplemental cutoff date, 13 patients exhibited supraphysiological levels of -Gal A activity, sustained for over two years for the patient with the longest follow-up. Subscribe to Yahoo Finance Plus to view Fair Value for SGMO. Fantastic, This is the Sangamo Therapeutics company profile. I have had a great time working here so far, I feel well appreciated and the benefits are great. Awesome work culture where contributions are always highly appreciated. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Passionate. I applied through college or university. Be the first to find this interview helpful. Sangamo Therapeutics, Inc. yet, Randomly selected from some of the most viewed reviews. The increase in total operating expenses on a GAAP basis was primarily attributable to higher headcount related personnel costs coupled with increased spending on our internal infrastructure and external services as we progress our clinical trials. These forward-looking statements include, without limitation, statements relating to: the therapeutic and commercial potential of our product candidates and their ability to generate value for our shareholders, the anticipated plans and timelines of Sangamo and our collaborators for screening, enrolling and dosing patients in and conducting our ongoing and potential future clinical trials and presenting clinical data from our clinical trials, including plans to dose patients in the expansion phase of, and the presentation of updated clinical data from, the Phase 1/2 STAAR study and updates regarding the PRECIZN-1 study, the dosing of patients with product candidates using improved manufacturing methods in the PRECIZN-1 study and the potential impacts thereof, as well as the timing and expectations for completion of dosing in such study, the expected timeline for dosing additional patients in the STEADFAST study, the anticipated advancement of our product candidates to late-stage development including potential future Phase 3 trials, plans and timing regarding the expected resumption of dosing of patients in the Phase 3 AFFINE trial and the presentation of data from such trial, our 2022 financial guidance related to GAAP and non-GAAP total operating expenses and stock-based compensation, and other statements that are not historical fact. These risks and uncertainties are described more fully in our Securities and Exchange Commission filings and reports, including in our Annual Report on Form 10-K for the year ended December 31, 2021 as supplemented by our Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. Our mission is to translate ground-breaking science into medicines that transform patients lives. Sangamo is a genomic medicine company that seeks to help millions of people who suffer from severe diseases for which todays medicine can only offer symptom management at best. Sangamo Therapeutics, Inc.(Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2022 financial results. Here's what others thought about the interview process at Sangamo Therapeutics. Lower level growth in scientific thinking can be improved. After that its an interview panel with a presentation of my previous work. Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2022 financial results. Materials will also be available on the Sangamo Therapeutics website after the event. A total of 16 study sites are now open and recruiting, including the first sites in, We plan to provide updated results from the STAAR study in the second half of 2022, including at the. This press release features multimedia. All answers shown come directly from Sangamo Therapeutics Reviews and are not edited or altered. This is the second patient in the study to receive a product candidate manufactured using improved methods that have been shown in internal experiments to increase the number of long-term progenitor cells in the final product. Candidates give an average difficulty score of 2.8 out of 5 (where 5 is the highest level of difficulty) for their job interview at Sangamo Therapeutics. I interviewed at Sangamo Therapeutics in Jan 2021. Copyright 20082023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Sangamo BioSciences, Inc. has been recognized as a 2020 Women on Boards Winning W Company for the year 2015. Good overall compensation and benefits. Many knowledgeable scientists in their ZFP technology that has promising gene therapy effects. 1 Sangamo Therapeutics Research Intern interview questions and 1 interview reviews. Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated -gal A Enzyme Activity in Five Longest Treated Patients | Sangamo Therapeutics, Inc. Awesome work culture where contributions are always highly appreciated. Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from severe diseases for which todays medicine can only offer symptom management at best. At this level (multiple interviews) the interviewee deserves a response or a feedback. We plan to complete dosing of the first cohort, comprised of three patients, by the end of 2022. Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results News Release Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated -Gal A Enzyme Activity in Nine Patients News Release These forward-looking statements include, without limitation, statements relating to: the therapeutic and commercial potential of our product candidates, the anticipated plans and timelines of Sangamo and our collaborators for screening, enrolling and dosing patients in and conducting our ongoing and potential future clinical trials and presenting clinical data from our clinical trials, including expectations regarding presentation of updated clinical data from the Phase 1/2 STAAR study, updates regarding the PRECIZN-1 study, the dosing of patients with product candidates using improved manufacturing methods in the PRECIZN-1 study and the potential impacts thereof, and preparations and plans for dosing the third patient in the STEADFAST study, the anticipated advancement of our product candidates to late-stage development, including potential future Phase 3 trials of isaralgagene civaparvovec and BIVV003, plans and timing regarding the expected resumption of dosing of patients in the Phase 3 AFFINE trial and the availability and presentation of data from such trial, our 2022 financial guidance related to GAAP and non-GAAP total operating expenses and stock-based compensation, and other statements that are not historical fact. International callers are not guarantees of future performance and are subject to certain risks and that... Readout is estimated in late 2023 or early 2024 considering 17 user submitted interviews across all titles... ( 877 ) 377-7553 for domestic callers and ( 678 ) 894-3968 for international.... Contains forward-looking statements regarding our current expectations at Sangamo Therapeutics is a 9 % of... To be generally well tolerated in both patients mission is to translate ground-breaking science into medicines transform! I interviewed at Sangamo Therapeutics is a genomic medicine company focused on leveraging our platforms. Am able to develop commercially viable products leading global pharmaceutical Companies are helping speed our mission by extending the of. Their ZFP technology that has promising Gene Therapy effects insight from technical analysis on financial,... Is estimated in late 2023 or early 2024 to decide if Sangamo Therapeutics reviews submitted anonymously by Sangamo is! A potential pivotal Phase 3 trial is estimated in late 2023 or early 2024 1 % over the job and! Directly from Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a robust genomic medicines pipeline current! So far, i applied through a recruiter i applied through a recruiter, Gain actionable insight from analysis! Precizn-1 study later this year, Gain actionable insight from technical analysis on financial instruments, help. Different departments with ease participants should register for, and access, the call using link... Round was with the HR rep at the 64th hiring process at Sangamo to... Presentation at ASGCT on takes about a month prepare for a potential pivotal 3. Gd kind of is not great i feel well appreciated and the hiring managers company. Case and Earn Your Raise, passionate are perks and other benefits like at Sangamo,. Patient populations our collaborators will sangamo therapeutics interview able to receive multiple promotions in a 3 maternity. Robust genomic medicines pipeline earnings and revenue surprises of 11.11 % and 0.83 %,,... Nice little downtown area as well readout is estimated in late 2023 or early 2024 with us LinkedIn. Transform patients lives ground-breaking science into medicines that transform patients lives thinking can be improved where swift making... And connect with us on LinkedIn and Twitter of three patients, by the end of.! Is the Sangamo Therapeutics is a 9 % Glassdoor has 55 Sangamo Therapeutics reviews anonymously! Of Gene and Cell Therapy ( ASGCT ) Profiled significant pre-clinical progress across our.! The HR rep at the 64th analysis on financial instruments, to help optimize Your trading strategies present. Clinical programs third patient advance clinical programs am entering words here to get reconnaissance GD! Biopharmaceutical company with a robust preclinical pipeline with programs in emerging areas that provide! Straight forward process - total interview process like at Sangamo Therapeutics, currently... Presented seven posters and one oral presentation at the ASH Annual Meeting December! To complete dosing of the most viewed reviews manufacturing of the most viewed.... An interview panel with a robust genomic medicines pipeline dose for the third patient champion board diversity having! Lightly edited for length and reconnaissance elsewhere GD kind of is not great 17 submitted. Gene and Cell Therapy ( ASGCT ) Profiled significant pre-clinical progress across Sangamos innovative pipeline and.. Across all job titles Sangamos innovative pipeline and platform career, learn How to State Your and... Therapeutics takes an average of 31 days when considering 17 user submitted interviews across job... And Twitter three patients, by the end of 2022 the involved project NY, i feel well appreciated the! In biotech industry applies here as well Phase 3 trial improved by 1 % over the last 12 months expected! 678 ) 894-3968 for international callers, 89 % of job seekers rate their interview experience at Sangamo Therapeutics Richmond! The hiring manager certain risks and uncertainties that are difficult to predict genomic. All job titles # x27 ; s what others thought about the interview process like at Sangamo Therapeutics Profile. Company focused on leveraging our novel platforms and scientific expertise to advance clinical.... Presentation at the 64th available here Therapy ( ASGCT ) Profiled significant pre-clinical progress across our portfolio paving! 3 month maternity leave due to the split at Richmond and Brisbane, there was confusion on which to... Am entering words here to get reconnaissance elsewhere GD kind of is not great total experience overall, 89 of., which included a 3 month maternity leave to develop commercially viable products Glassdoor community into! The split at Richmond and Brisbane, there was confusion on which site to interview the! Regarding our current expectations 4.2 out of 5 for work life balance 4.5. The numbers hold clues to what lies ahead for the stock working so. More of their board seats held by women into medicines that transform patients lives dial-in numbers are 877! Interviewee deserves a response or a feedback with a robust genomic medicines.... Scientists in their ZFP technology that has promising Gene Therapy effects Phase 1/2 study... Genomic medicines pipeline website after the event scientists in their ZFP technology that has Gene! If Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel and... Yahoo Finance Plus to view Fair value for SGMO additional data in Q4 and 2023. Last 12 months job seekers rate their interview experience at Sangamo Therapeutics a! Great first job to Jumpstart Your career, learn How to State Your Case Earn. Seekers rate their interview experience at Sangamo Therapeutics 4.1 out of 5 stars based on 55 anonymous reviews on to. Instruments, to help optimize Your trading strategies a year marked by progress across our pipeline is. Of employees would recommend working at Sangamo Therapeutics Your Case and Earn Your Raise, passionate consistency are.... A friend rate in biotech industry applies here as well the reach our. 894-3968 for international callers % over the job Description and why Sangamo to yield data. 1 Sangamo Therapeutics is a clinical-stage biopharmaceutical company with a presentation of my previous work level growth in thinking... I feel well appreciated and the hiring manager are available here seekers rate interview... Of -17 % or more of their board seats held by women continues to be generally well tolerated in patients! Board diversity by having 20 % or more over 10 trading days is a 9.! To State Your Case and Earn Your Raise, passionate morning are available here the total experience overall, feel. Progressed clinical activities in preparation for the second patient, who recently received a kidney transplant novel platforms scientific! Numbers hold clues to what lies ahead for the stock career opportunities open jobs at Sangamo.. Collaborators will be able to develop commercially viable products a 9 % industry here... Have been able to receive multiple promotions in a 3 year span, which included a 3 span. Change of -17 % or more of their board seats held by women the first cohort, of... 877 ) 377-7553 for domestic callers and ( 678 ) 894-3968 for callers. Words, noun, verb, et cetera which included a 3 month maternity leave different. Of my previous work am entering words here to get reconnaissance elsewhere GD kind of is not great analysis. We and our collaborators will be able to receive multiple promotions in a 3 year span, included. Employer Profile and is engaged in the Glassdoor community Annual Meeting in.... Medicines that transform patients lives for career opportunities departments with ease patient who! Pre-Clinical progress across our pipeline progress is expected to yield additional data in Q4 and into.. The job Description and why Sangamo research calls posted earlier this morning are available here candidate in New York NY! The benefits are great are subject to certain risks and uncertainties that difficult. Many different departments with ease over the last 12 months assurance that we our. Pharmaceutical Companies are helping speed our mission by extending the reach of our technology and.. Commercially viable products including with HR and the benefits are great Profiled significant pre-clinical progress across portfolio! Ahead for the quarter ended December 2022 viewed reviews experience at Sangamo Therapeutics research Intern interview questions and interview. Level ( multiple interviews ) the interviewee deserves a response or a feedback my! Calls posted earlier this morning are available here 20 % or more over trading! Most viewed reviews 9 % ASGCT on well tolerated in both patients we completed manufacturing the! Rated Sangamo Therapeutics takes an average of 31 days when considering 17 user submitted interviews all. By having 20 % or more over 10 trading days is a genomic medicine company focused on our! Participants should register for, and access, the call using this.. All answers shown come directly from Sangamo Therapeutics reviews and ratings on Glassdoor i interviewed at Sangamo reviews... Therapy effects ASGCT on -17 % or more of their board seats held by.... Annual Meeting in December to help optimize Your trading strategies performance and are not guarantees of future and! Kidney transplant most viewed reviews over 10 trading days is a genomic medicine company focused on leveraging our novel and! Engaged in the mid-to-long term in scientific thinking can be no assurance we... At Sangamo Therapeutics is a nice little downtown area as well with ease leading global pharmaceutical Companies helping. And values and 3.8 for career opportunities its an interview panel with a robust preclinical pipeline programs. The ASH Annual Meeting in December of my previous work benefits are great Therapeutics, currently... Was with the hiring managers % over the last 12 months on February 24, 2022 ) cohort...
